NEW YORK – Pillar Biosciences said today that it has signed a comarketing agreement with China's MGI Tech for its Onco/Reveal next-generation sequencing panels.
Under the terms of the agreement, MGI, which markets the MGISP-960 and -100 automated high-throughput library prep systems, will market the Pillar panels to its sequencing customers outside the US.
"With MGI's sample prep automation, the hands-on time for our simplified library prep workflows has reached an unprecedented level of efficiency," Pillar CEO Gang Song said in a statement.
Boston-based Pillar said that its NGS panels featuring SLIMamp target enrichment chemistry are now compatible with the MGI, Illumina, and Thermo Fisher Scientific Ion Torrent sequencing platforms.
The comarketing deal is the second in as many weeks for MGI — the BGI subsidiary signed a similar deal with Twist Bioscience Oct. 30, covering target enrichment products in the Europe and Asia Pacific regions.
Pillar announced a strategic partnership and joint venture with China Biotech Services Holdings in January.
"This agreement combines two technologies that really complement each other," added MGI President Duncan Yu. "We're excited to work with Pillar to deliver seamlessly integrated automated library preparation."